Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Video Highlights: New Data on Investigational Long-Acting ART

March 8-11, 2020; Boston, Massachusetts
Watch this short video highlight to hear about the latest data from CROI 2020 on long-acting ART options.
Babafemi Taiwo, MBBS
Released: March 14, 2020

Information on this Educational Activity

Faculty

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

Limited treatment-emergent capsid resistance occurred after 28 weeks of treatment with oral or subcutaneous lenacapavir plus FTC/TAF from ID Week 2021 reported by Clinical Care Options (CCO)

Released: October 5, 2021

Switch to DTG/3TC shows high levels of efficacy, favorable safety and tolerability, and high barrier to resistance through 3 years from IDWeek 2021 presented by Clinical Care Options (CCO)

Released: October 5, 2021

Diapositivas descargables creadas por expertos que analizan los desarrollos clínicos más importantes en el manejo del VIH desde el año pasado

Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD Daniel R. Kuritzkes, MD Darcy Wooten, MD
Released: October 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue